Template
Capital Change Notice

Updated as at February 2025

Please do not amend or delete individual rows. As this template relates to prescribed content, changes to content should only be made where it is clearly indicated that this is permitted, otherwise, if an Issuer considers a particular element does not apply, mark the row as N/A. Any other changes to this prescribed form must first be approved by NZX as required under NZX Listing Rule 3.26.1.

Section 1: Issuer information	
Name of issuer	Ryman Healthcare Limited
NZX ticker code	RYM
Class of financial product	Unquoted performance share rights
ISIN (If unknown, check on NZX website)	NZRYME0001S4
Currency	NZD
Section 2: Capital change details	
Number issued/acquired/redeemed	16,295
Nominal value (if any)	N/A
Issue/acquisition/redemption price per security	Nil
Nature of the payment (for example, cash or other consideration)	16,295 of the performance share rights granted to senior executives under the LTIP vest on 31 August 2026, and convert into 16,295 Ordinary Shares at such time, for no cash consideration. These share rights are the final tranche of rights granted as part of the transition from the previous leadership share scheme, with time-based vesting conditions only. Further details of the LTIP and such performance share rights are provided in RYM's annual report.
Amount paid up (if not in full)	Fully Paid
Percentage of total class of Financial Products issued/acquired/redeemed/ (calculated on the number of Financial Products of the Class, excluding any Treasury Stock, in existence)[1]	0.001604%
For an issue of Convertible Financial Products or Options, the principal terms of Conversion (for example the Conversion price and Conversion date and the ranking of the Financial Product in relation to other Classes of Financial Product) or the Option (for example, the exercise price and exercise date)	N/A
Reason for issue/acquisition/redemption and specific authority for issue/acquisition/redemption/ (the reason for change must be identified here)	Vesting and exercise of 16,295 of the performance share rights under the LTIP (see details above) authorised by a board resolution dated 31 August 2026.

[1] The percentage is to be calculated immediately before the issue, acquisition, redemption or Conversion.

Total number of Financial Products of the Class after the issue/acquisition/redemption/Conversion (excluding Treasury Stock) and the total number of Financial Products of the Class held as Treasury Stock after the issue/acquisition/redemption.	1,015,745,376 Ordinary Shares (excluding Treasury Stock) Nil Treasury Stock
In the case of an acquisition of shares, whether those shares are to be held as treasury stock	N/A
Specific authority for the issue, acquisition, or redemption, including a reference to the rule pursuant to which the issue, acquisition, or redemption is made	Board resolution dated 31 August 2026; permitted under NZX Listing Rule 4.6.1
Terms or details of the issue, acquisition, or redemption (for example: restrictions, escrow arrangements)	Ordinary Shares ranking equally with the existing Ordinary Shares on issue in RYM
Date of issue/acquisition/redemption[2]	31 August 2026
Section 3: Disclosure required for Placements made under Rule 4.5.1 *[Issuers may opt to release Section 3 information (if not already done so) in a separate announcement within five Business Days of the issuance. Delete this Section 3 if capital change is not the result of a Placement under Rule 4.5.1]*	
Details of the approach in identifying investors who were able to participate in the offer and how their respective allocations in the offer were determined. The explanation must set out the key objectives and criteria the Issuer adopted in the allocation process, whether one of those objectives was a best effort to allocate on a pro rata basis to existing holders of the Issuer's Equity Securities, and any significant exceptions or deviations from those objectives and criteria.	N/A
Section 4: Authority for this announcement and contact person	
Name of person authorised to make this announcement	Morgan Powell
Contact person for this announcement	Morgan Powell
Contact phone number	+64 21 246 6361
Contact email address	morgan.powell@rymanhealthcare.com
Date of release through MAP	31 August 2026

[2] Continuous issuers using this form in reliance on Rule 3.13.2, please indicate the period during which the relevant issue/acquisition/redemptions were made (for example, 1 January 2019 to 31 January 2019).